Transmyocardial revascularization (TMR) can improve refractory angina but does not consistently demonstrate an effect on myocardial function. Recent studies suggest a synergistic effect between TMR and exogenously supplied growth factors. We evaluated the clinical role of intramyocardial injection of autologous platelet-rich plasma (PRP) in conjunction with TMR. Twenty-five nonrevascularizable patients with class III/IV angina underwent minimally invasive sole therapy TMR during a 5-year period at a single institution. Group 1 (14 patients) underwent TMR alone while group 2 (11 patients) underwent TMR plus injection of PRP (Magellan plasma separator) between TMR channels. Blinded angina assessment and ejection fraction (EF) were measured preoperatively and at 6 months postoperatively. Baseline EF (57 ± 10% vs. 50 ± 7%), angina class (3.7 ± 0.5 vs. 3.7 ± 0.5), and the number of channels (48 ± 5 vs. 48 ± 4) were statistically similar in both groups. At 6 months, two class angina relief was similar in both groups (92% vs. 100%, p = 0.4); however, the TMR + PRP group had a lower average angina score (1.3 vs. 0.4, p = 0.07) and more were angina free (23% vs. 78%, p = 0.04) than the TMR-alone group. EF improved in the TMR + PRP group (−2.0% vs. +9.0%, p = 0.07) compared to the TMR-alone group. Two 30-day morbidities occurred in the TMR-alone group (atrial fibrillation and left pleural effusion) and one mortality occurred in the TMR + PRP group. Intramyocardial injection of autologous PRP combined with TMR may be more efficacious at relieving angina and improving myocardial function than TMR alone.
INTRODUCTION
but not yet as a therapeutic option for treating myocardial ischemia. The purpose of this study was to evaluate the clinical Transmyocardial revascularization (TMR) provides significant angina relief in patients with medically re-role of intramyocardial injection of autologous PRP combined with TMR in patients with medically refrac-fractory, "no-option," end-stage coronary artery disease (2). Decreased hospitalizations, less medication usage, tory class III/IV angina. and improved exercise times are also associated with TMR's overall improvement in patients' quality of life MATERIALS AND METHODS (5). However, sole TMR has not been shown to consistently improve myocardial function (7) .
From July 2002 to August 2007, 25 patients with medically refractory class III/IV angina who had no con-Recent studies have shown a possible synergistic effect with combined TMR and exogenous administration ventional revascularization options were referred to a single institution for sole therapy TMR. Patients were of growth factors in improving angina and possibly myocardial function (11). Clinically, autologous growth deemed inoperable for percutaneous coronary intervention or redo coronary artery bypass grafting if coronary factors can be found in concentrated, centrifuged blood plasma and platelet separation in the form of platelet-arterial targets were measured as less than 1 mm in diameter. All patients underwent preoperative persantine rich plasma (PRP) (24) . PRP has been used in orthopedic, dental, and sternal wound healing platforms (23), Cardiolite nuclear medicine stress testing and had docu- mented reversible ischemia in the anterior, lateral, or in-and Cardiolite nuclear medicine stress testing with computer-calculated ejection fraction (EF) was performed ferior walls of the left ventricle.
As previously described (25), holmium-YAG laser within 6 months preoperatively and at 6 months postoperatively. Study end-points at 6 months included a non-TMR (CardioGenesis Corp., Irvine, CA, USA) was performed using a minimally invasive 2-3-inch left antero-surgeon blinded angina assessment using Canadian Cardiovascular Society Class Angina Score, change in ejection lateral thoracotomy and a single 5-mm voice-activated robotic-controlled (AESOP, Computer Motion, Santa fraction, hospital readmissions, and morbidity and mortality. Statistical analyses were performed using Wilcoxon Barbara, CA, USA) thoracoscope. One millimeter transmural channels, 1 cm 2 apart, were created in the distal Paired Rank Sum tests. This study was approved by the Institutional Review Board/New Procedures Committee two thirds of the left ventricle. All patients were intraoperatively monitored with radial and pulmonary arterial at Peninsula Regional Medical Center, and detailed informed consent was obtained from each patient. Only catheters. Nitroglycerin (15 µg/min) and lidocaine (2 mg/min) infusions were started 30 min prior to and primary health care providers practicing at the single institution were allowed access to confidential individual given during the operative procedure. Patients were divided into two groups. Group 1 (14 patients) underwent patient information. Others were provided with data summary only. sole therapy TMR alone. Group 2 (11 patients) underwent TMR plus intramyocardial injection of PRP.
RESULTS Autologous PRP was obtained by removing two 60ml syringes of whole blood from each group 2 patient Preoperative patient demographics were similar between TMR and TMR + PRP groups (Table 1) , includ-15 min prior to making an incision. The blood was anticoagulated with 8 ml per syringe of sodium citrate (Bax-ing average age (60 ± 11 vs. 65 ± 11 years, p = 0.3), baseline EF (57 ± 11% vs. 50 ± 7%, p = 0.1), and base-ter Healthcare, Round Lake, IL, USA); 6 ml of PRP was isolated using a point-of-care Magellan cell separator line angina class (3.7 ± 0.5 vs. 3.7 ± 0.5, p = 0.9). Operative characteristics, including the number of TMR (Arteriocyte Medical Systems, Cleveland, OH, USA) during 16 min of centrifugation. Using a tuberculin 27-channels (48 ± 5 vs. 49 ± 4, p = 0.9) and operative times (group 1 80.3 ± 24.6 vs. group 2 73.0 ± 13.0 min, p = gauge needle on a 1-ml syringe, 0.5-0.6 ml aliquots were injected intramyocardially in a perpendicular fash-0.4), were also similar between groups. Tables 2, 3, 4, and 5 represent the blood characteristics of 6.0 cc of ion between channels following the TMR procedure. Intraoperative transesophageal echocardiography showed PRP obtained from 60 cc of whole blood (n = 9). Six-month follow-up occurred in 13/14 patients in no evidence of endoventricular bubble infiltration during PRP injection. group 1 and 9/11 patients in group 2. Two patients (one from each group) were lost to follow-up after their initial Baseline demographics were collected prospectively 60-year-old male with a baseline EF of 35% who had both congestive heart failure symptoms and class IV angina. He was discharged uneventfully on POD 1 with no arrhythmias, and reportedly doing well until POD 11 1-month postoperative appointment. Both of these pawhen he suddenly collapsed on a commode, and was tients had significant improvement in angina after their found unresponsive, hypoxic, and in electromechanical procedures. Follow-up in one group 2 patient could not dissociation. Family declined autopsy. Overall morbidity be achieved because of a 30-day mortality. A compariwas 8% (2/25). Rapid atrial fibrillation occurred on son of angina scores at baseline and 6 months postoperapostoperative day 3 in a TMR-alone patient, who was tively for both groups are shown in Figure 1 . When sucdischarged on day 5 following medical conversion to cessful angina relief was defined as two class reduction normal sinus rhythm. A second patient who underwent in CCS angina score, both groups achieved significant TMR alone was readmitted on POD 14 with symptomimprovement at 6 months (92% for TMR alone, 100% atic left pleural effusion, and was discharged uneventfor TMR + PRP, p = 0.4), although absolute angina scores fully 2 days following thoracentesis. No postoperative trended to be less in the TMR + PRP group (1.3 for ventricular arrhythmias, bleeding, or transfusions were group 1 vs. 0.4 for group 2, p = 0.07). At 6 months, observed. however, 78% (7/9 patients) of the TMR + PRP group were angina free (CCSAS zero), compared to 23% of DISCUSSION the TMR alone group (3/13 patients), as shown in Figure  2 (p = 0.04).
Transmyocardial revascularization is a recommended surgical procedure (6) to treat patients with medically Paired baseline and 6-month Cardiolite nuclear stress tests were performed to determine changes in EF, if any. refractory class III/IV angina who are not candidates for conventional revascularization (4). Randomized pro-We chose this method of testing because it was readily available in all study patients at the single institution.
spective trials have demonstrated a significant improvement in angina, a reduction in cardiac medications and Regional myocardial perfusion in these Cardiolite nuclear stress tests was subjectively analyzed by 20 differ-readmissions, and improved event-free survival when sole therapy TMR patients are compared to maximal ent cardiologists at the single institution. This subjective analysis was thought to have inherent bias between the medical therapy patients (2). These benefits have been shown to last as long as 5 years (1). However, TMR is examiners. Therefore, the changes in myocardial perfusion noted after TMR and/or TMR + PRP were not not 100% effective. In approximately 25% of patients treated with sole therapy TMR, angina relief is not sig-included in this preliminary study as a method of comparison. However, because the EF was an objective, nificantly improved at 1 year (5). Furthermore, complete angina amelioration was even less impressive in these computer-calculated value, the average numbers be- studies, with only approximately one third becoming an-some insight into the importance of platelet-derived growth factors and stem cells in linking the mechanism gina free (10). Finally, demonstration of improved myocardial perfusion and ejection fraction by TMR has been of TMR and angiogenesis. Hughes and Lowe concluded that TMR-induced neovascularization is due to an upregu-inconsistent.
Recent studies have evaluated the role of exoge-lation of the angiogenic cascade secondary to the inflammatory response after laser treatment (13). Alturi and nously administered biologic substances, such as growth factors and stem cells, as new therapeutic options for colleagues demonstrated that the acute healing phase of the laser injury involves an upregulation of injured myo-medically refractory angina. Intramyocardial injection of specific growth factors, such as vascular endothelial cytes, platelet activation with growth factor release from the thrombus that forms within the laser channel, and growth factors (16) and fibroblastic growth factor, may provide angina improvement (17) and improve ventricu-the recruitment of intrinsic myocardial stem cells (3). Lutter et al. suggested that administration of fibroblastic lar function (22) in inoperable patients. Similarly, intramyocardial injection of autologous bone marrow-derived growth factor may enhance TMR's angiogenic response (18) . Furthermore, Patel and colleagues have recently mononuclear stem cells such as CD34 + (15) and AC133 + (20) stem cells have been shown to improve angina and demonstrated enhanced stem cell retention when stems cells are injected into the border zone of the TMR chan-myocardial perfusion in patients with refractory ischemia. Animal studies of TMR and gene therapy confirm nel, suggesting that the microenvironment created by TMR may be important for stem cell retention following these findings of improvement in contractility (12). This evidence suggests that isolated intramyocardial growth myocardial ischemia (19) . Autologous platelet-rich plasma has been used in or-factor or stem cell injection therapy may be associated with angina relief and improved regional myocardial thopedic, dental, and wound healing applications (8) with improved clinical outcomes. PRP is readily available function and perfusion.
Animal models of myocardial ischemia can provide from the centrifugation of whole blood and the concentration of plasma, and can be easily obtained within 15 min in the operating room. Qualitative assessment of PRP typically yields platelet counts that are approxi- ferentiation of human mesenchymal stem cells (14) . Finally, PRP has known clinical properties promoting he-PDGF, platelet-derived growth factor; TGF, transforming growth facmostasis when combined with thrombin. Because PRP tor; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; EGF, endothelial growth factor. is autologous, readily available from a minimal amount of peripheral blood centrifugation, and contains many REFERENCES angiogenic factors, we hypothesized that PRP injection into chronically ischemic myocardium may provide a
